drugset / Trial / NCT01039194

Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

NCT01039194

Phase 1 Completed 18 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-label

Summary

The purpose of the study is to find out if the plasma concentration of galantamine extended release is changed when BMS-708163 is administered at the same time.

Timeline

Start
2010-01
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Avagacestat Small molecule 125 mg Oral
Comparator Galantamine Small molecule 16 mg Oral

Indications